Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
Survival Benefit in Children with Progeria Published in JAMA 2018 NDA Filing Planned in 2019 PALO ALTO, Calif., Dec. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and ... Biopharmaceuticals, FDA Eiger BioPharmaceuticals, Lonafarnib, Progeria Syndrome, Progeroid Laminopathies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 19, 2018 Category: Pharmaceuticals Source Type: news

Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Indivior PLC Announces Plan for Commercial Launch in February 2019 with 50 Sales Representatives CUPERTINO, Calif., Dec. 19, 2018 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: IND... Biopharmaceuticals, Product Launch DURECT, PERSERIS, risperidone, Schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 19, 2018 Category: Pharmaceuticals Source Type: news

Erasca Launches with $42 Million Series A Financing to Support Bold Mission of Erasing Cancer
Company, co-founded by physician-turned-venturepreneur Dr. Jonathan E. Lim, is targeting undisclosed biological drivers of cancer SAN DIEGO, Dec. 18, 2018 -- (Healthcare Sales & Marketing Network) -- Erasca, a company dedicated to advancing exceptional... Biopharmaceuticals, Oncology, Venture Capital Erasca (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2018 Category: Pharmaceuticals Source Type: news

Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Subgroup analyses demonstrate consistent benefit in subgroups of patients with a more concerning prognosis such as those with liver metastases, PR-negative disease, high tumor grade, or shorter treatment-free interval INDIANAPOLIS, Dec. 18, 2018 -- (Hea... Biopharmaceuticals, Oncology Eli Lilly, Verzenio, abemaciclib, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2018 Category: Pharmaceuticals Source Type: news

Proteostasis Therapeutics Announces Global License Agreement with Genentech
Agreement Covers Small Molecule Modulators of the Cellular Proteostasis Network BOSTON, Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to th... Biopharmaceuticals, Licensing Proteostasis Therapeutics, Genentech, Roche Group (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 17, 2018 Category: Pharmaceuticals Source Type: news

Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
INDIANAPOLIS, Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the ef... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis, SPIRIT-H2H trial (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 17, 2018 Category: Pharmaceuticals Source Type: news

Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed Q2 2019 New Drug Application (NDA) Resubmission Planned Management to Host Conference Call at 8:30 a.m. EST SAN DIEGO, Dec... Biopharmaceuticals Evofem Biosciences, Amphora, birth control (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 17, 2018 Category: Pharmaceuticals Source Type: news

PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
WALTHAM, Mass., Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- PharmaEssentia, a global biopharmaceutical company focused on developing and commercializing novel treatments for treatment of rare diseases, today announced that the Committee for... Biopharmaceuticals, Regulatory PharmaEssentia, Besremi , polycythaemia vera (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 17, 2018 Category: Pharmaceuticals Source Type: news

Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
Lilly will leverage Evidation's Andromeda data platform to analyze large scale data aimed at uncovering novel digital measures of health INDIANAPOLIS and SAN MATEO, Calif., Dec. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Compan... Biopharmaceuticals, Healthcare Information Technology Eli Lilly, Evidation Health, Andromeda data (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2018 Category: Pharmaceuticals Source Type: news

BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance
STOCKHOLM, Dec. 14, 2018 -- (Healthcare Sales & Marketing Network) -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade Commission (FTC) clearance to license ... Biopharmaceuticals, Neurology, Licensing BioArctic, AbbVie, alpha-synuclein, Parkinson's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2018 Category: Pharmaceuticals Source Type: news

CTI BioPharma Announces Restructuring Plan
Fifty percent reduction in workforce expected to improve efficiencies and preserve capital for pacritinib development SEATTLE, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (NASDAQ: CTIC) announced today a restructuring... Biopharmaceuticals, Personnel CTI BioPharma, pacritinib, myelofibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET(TM) Immunotherapy Drug Candidates
Celgene licenses two TriNKET™ immunotherapy drug candidates built by Dragonfly for $24m plus milestones and royalties WALTHAM, Mass., Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the ... Biopharmaceuticals, Oncology, Licensing Dragonfly Therapeutics, Celgene, TriNKET, Immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news

Aethlon Announces Appointment of Timothy Rodell as Interim Chief Executive Officer
SAN DIEGO, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today the appointment of Timothy C. Rodell, M.D., FCCP, as Inte... Devices, Oncology, Personnel Aethlon Medical, Hemopurifier, immunotherapeutic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news

Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials HERTFORDSHIRE, England and PITTSBURGH, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N... Biopharmaceuticals, Generics, Endocrinology, Litigation Mylan, Sanofi, Lantus, insulin glargine, Lantus SoloSTAR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news

FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
INDIANAPOLIS, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricit... Biopharmaceuticals, FDA Eli Lilly, Baricitinib, Systemic Lupus Erythematosus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news

Ampio Updates Regulatory Status for Ampion
ENGLEWOOD, Colo., Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion. As announced on November 26, 2018, statisticians representing Ampio and the U.S. Fo... Biopharmaceuticals, FDA Ampio Pharmaceuticals, Ampion, osteoarthritis, total knee (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news

Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and Pricing
NORTHBROOK, Ill., Dec. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas today announced that Lei Ding has been promoted to vice president, Payer Strategy, Contracts and Pricing. In this role, Ding will be responsible for leading these areas ... Biopharmaceuticals, Personnel Astellas (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 12, 2018 Category: Pharmaceuticals Source Type: news

Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets
Company Initiates Voluntary Chapter 11 Process to Effectuate Sale; Secures Commitment for DIP Financing to Support Normal-Course Operations NEW YORK, Dec. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP)... Biopharmaceuticals, Gastroenterology, Mergers & Acquisitions Synergy Pharmaceuticals, Bausch Health, Bausch & Lomb, TRULANCE, plecanatide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 12, 2018 Category: Pharmaceuticals Source Type: news

Lilly and AC Immune Announce License and Collaboration Agreement
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF6... Biopharmaceuticals, Neurology, Licensing Eli Lilly, AC Immune, Morphomer tau aggregation, Alzheimer's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 12, 2018 Category: Pharmaceuticals Source Type: news

Magnetic Insight Raises $18M to Support Commercial Growth of Magnetic Particle Imaging in Cell Therapy, Vascular and Oncology Applications
ALAMEDA, Calif., Dec. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Magnetic Insight, Inc., a developer and manufacturer of transformational in vivo imaging platforms, announced a Series A financing led by 5AM Ventures. The proceeds will allow the... Devices, Radiology, Venture Capital, Personnel Magnetic Insight, Magnetic Particle Imaging, imaging, MOMENTUM MPI system (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 12, 2018 Category: Pharmaceuticals Source Type: news

NOVADIP BIOSCIENCES Appoints Jeff Abbey as CEO
MONT-SAINT-GUIBERT, Belgium, December 12, 2018 -- (Healthcare Sales & Marketing Network) -- NOVADIP BIOSCIENCES, a regenerative medicine company and pioneer in the growth of 3-dimensional tissues derived from adipose stem cells for hard and soft tissue re... Regenerative Medicine, Personnel NOVADIP BIOSCIENCES, 3-dimensional tissues (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 12, 2018 Category: Pharmaceuticals Source Type: news

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent MARLBOROUGH, Mass., Dec. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the United States (U.S.... Devices, Cardiology, Litigation Boston Scientific, Edwards Lifesciences, Sapien 3, aortic valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

Aqil Chishty Named Chief Operating Officer of Woundtech
FT. LAUDERDALE, Fla., Dec. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Woundtech, a leading provider of technology-enabled wound management services, today announced that Aqil Chishty has been formally named Chief Operating Officer (COO). Aqil ... Devices, Wound Care, Personnel Woundtech, telehealth (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

Positive Payor Policy Covering coflex(R) by Select Health of South Carolina for the Surgical Treatment of Lumbar Spinal Stenosis
Coverage policy issued by Select Health of South Carolina Select Health of South Carolina serves more than 364,000 lives Policy exclusively covers coflex® Interlaminar Stabilization® coflex® is a non-fusion, motion-preserving implant f... Devices, Orthopaedic, Neurosurgery, Reimbursement Paradigm Spine, coflex, Interlaminar Stabilization, RTI Surgical (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer(TM) as Published in JACC
VANCOUVER, Dec. 11, 2018 -- (Healthcare Sales & Marketing Network) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technolo... Devices, Interventional, Cardiology Neovasc, Reducer, angina (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
ALISO VIEJO, Calif., Dec. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Avanir Pharmaceuticals, Inc. today announced that it will terminate the license agreement with Optinose for intranasal migraine medication ONZETRA® Xsail® (sumatriptan... Biopharmaceuticals, Neurology, Licensing Avanir Pharmaceuticals, Optinose, ONZETRA Xsail, migraine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy
SEATTLE, Dec. 11, 2018 -- (Healthcare Sales & Marketing Network) -- LumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement wit... Devices, Ophthalmology, Distribution LumiThera , Miloftalmica, photobiomodulation, Valeda Light Delivery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

GenEdit Closes $8.5 million Series Seed Financing
BERKELEY, Calif., Dec. 11, 2018 -- (Healthcare Sales & Marketing Network) -- GenEdit, Inc., a developer of novel polymer nanoparticle technology platform for non-viral-based delivery of gene therapeutics, today announced the completion of a $8.5 million S... Regenerative Medicine, Venture Capital GenEdit, gene therapeutics, CRISPR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2018 Category: Pharmaceuticals Source Type: news

Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer First regulatory designation for M7824 following recent presentation of first clinical data in BTC BTC is a group of rare, aggressive g... Biopharmaceuticals, Oncology, FDA Merck KGaA, Immunotherapy, M7824, Biliary Tract Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Perrigo Announces the Launch of an AB Rated Generic Version of Topicort(R) Topical Spray 0.25%
DUBLIN, Dec. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is ind... Biopharmaceuticals, Generics, Product Launch Perrigo, Topicort, desoximetasone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Rockwell Medical, Inc. Appoints New Vice President, Operations
Completes Build-Out of Senior Leadership Team by Stuart Paul WIXOM, Mich., Dec. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical") today announced that M... Biopharmaceuticals, Personnel Rockwell Medical, Triferic, ferric pyrophosphate, hemodialysis, Calcitriol (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients
Data shows current guidelines exclude many patients with medically relevant genetic changes SAN FRANCISCO, Dec. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Current guidelines for genetic testing of breast cancer patients miss as many patients... Diagnostics, Oncology Invitae Corp, TME Breast Care Network, BRCA1, BRCA2 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Atia Vision, A Shifamed Portfolio Company, Closes $10M In Series C Financing
CAMPBELL, Calif., Dec. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular accommodating intraocular lens, announced today the c... Devices, Ophthalmology, Venture Capital Atia Vision, Shifamed, intraocular lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine Safety and tolerability profile of rimegepant with up to one year of dosing in patients with migraine is consistent with previous Phase 1-3 clinical experience No l... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, rimegepant, migraine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer
Dr. Tse's Extensive Track Record in Oncology Early Clinical Development Will Strengthen CStone's Core Competence as a Clinical Development Engine and Solidify CStone's Position Among Leading Innovative Biopharma Companies in China SUZHOU, China, Dec. 10... Biopharmaceuticals, Oncology, Personnel CStone Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Contego Medical Receives 510(k) Clearance for the Vanguard IEP Peripheral Angioplasty System with Integrated Embolic Protection
RALEIGH, N.C., Dec. 7, 2018 -- (Healthcare Sales & Marketing Network) -- Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Vanguard IEP® Peripheral Balloon Angioplasty System with Int... Devices, Interventional, FDA Contego Medical, Vanguard IEP, Peripheral, Angioplasty, embolic protection (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 7, 2018 Category: Pharmaceuticals Source Type: news

Genisphere Appoints Biopharmaceutical Veteran, Brian P. McVeigh, to Its Board of Directors
HATFIELD, Pa., Dec. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Genisphere LLC, provider of the 3DNA® nanotechnology drug delivery platform, announced Brian P. McVeigh has joined the company's Board of Directors, bringing expertise to expand ... Biopharmaceuticals, Drug Delivery, Personnel Genisphere, 3DNA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2018 Category: Pharmaceuticals Source Type: news

Akero Therapeutics Appoints Mark Iwicki to its Board of Directors
SAN FRANCISCO, Dec. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Akero Therapeutics Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced... Biopharmaceuticals, Personnel Akero Therapeutics, non-alcoholic steatohepatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2018 Category: Pharmaceuticals Source Type: news

Accuray CyberKnife(R) System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade
Next-Generation Accuray Precision® Treatment Planning System With the CyberKnife VOLO™ Optimizer Also Reduces Treatment Planning Times Up to 90 Percent, Enabling Clinicians to Treat More Patients Each Day SUNNYVALE, Calif., Dec. 6, 2018 -- (Healthca... Devices, Oncology, Product Launch Accuray, CyberKnife, VOLO Optimizer, radiotherapy, radiosurgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2018 Category: Pharmaceuticals Source Type: news

QxMD Software’s Content Engagement Platform Tops 200 Million Annual Views by Healthcare Professional (HCP) Members
QxMD Pathways sets new membership engagement milestone, exceeds 200 million mark for annual aggregate views across mobile and web platform channels VANCOUVER, Canada, December 6, 2018 -- (Healthcare Sales & Marketing Network) -- QxMD Software Inc., a d... Healthcare Information Technology QxMD Software, QxMD Pathways (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Olympus Spiration(R) Valve System Is FDA Approved for the Endobronchial Treatment of Emphysema
Minimally invasive therapy offers non-invasive patient screening with short procedure time and is shown to improve lung function and quality of life CENTER VALLEY, Pa., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Olympus, a global technol... Devices, FDA Olympus Medical Systems, Spiration Valve, Emphysema, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Vast Therapeutics Announces Series A Funding
Partnership with Shionogi Ltd Includes Collaboration for Development of Proprietary Nitric Oxide Powder Technology for Antimicrobial Resistant Bacteria in Respiratory Applications DURHAM, N.C., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Venture Capital Vast Therapeutics, KNOW Bio, nitric oxide, cystic fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

MiMedx Announces Leadership Changes And Promotions
Deep Management and Healthcare Expertise Complements Proprietary Product Platform MARIETTA, Ga., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therape... Biopharmaceuticals, Regenerative Medicine, Personnel MiMedx, PURION process (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Bausch and Lomb Receives 510(K) Clearance From FDA For Bausch and Lomb Ultra(R) Multifocal For Astigmatism Contact Lenses
BRIDGEWATER, N.J., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) cleara... Devices, Ophthalmology, FDA Bausch & Lomb, Ultra Multifocal, Astigmatism, Contact Lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

MiMedx Announces Organizational Realignment Program
Plan Will Improve Cost Structure and is Designed to Position Business for Long-Term Success MARIETTA, Ga., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative a... Biopharmaceuticals, Regenerative Medicine, Personnel MiMedx, PURION process (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Subtle Medical Receives FDA 510(k) Clearance and CE Mark Approval for SubtlePET(TM)
First AI Product Cleared for Medical Imaging Enhancement. MENLO PARK, Calif., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Subtle Medical, a privately-held medical device company focused on improving medical imaging efficiency and patient ... Devices, Radiology, FDA, Regulatory Subtle Medical, SubtlePET, imaging (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Icagen enters into Collaboration to Develop and Commercialize Therapy for Neurological Diseases
ollaboration includes the initial program utilizing Icagen's Drug Discovery Platform. DURHAM, N.C., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Icagen announced today that they have entered into a license and collaboration agreement with ... Biopharmaceuticals, Neurology, Licensing Icagen , Roche Group (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

EUSA Pharma Appoints Jeffrey S. Hackman as President US Operations
EUSA to Open New US Headquarters in Boston, MA Significant US Expansion to Complete EUSA's Transatlantic Commercial Platform BOSTON and HEMEL HEMPSTED, England, December 5, 2018 -- (Healthcare Sales & Marketing Network) -- EUSA Pharma (EUSA), a glob... Biopharmaceuticals, Oncology, Personnel EUSA Pharma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Panther Orthopedics Announces Successful Clinical Use of the PUMA System (TM)
TAIPEI, Taiwan, Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Panther Orthopedics, Inc., a medical device company headquartered in San Jose, California, is pleased to announce the successful clinical use of its innovative flexible fixation dev... Devices, Orthopaedic Panther Orthopedics, flexible fixation, PUMA System, PUMA Body (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

MED-Fibers Announces New GrabHold(TM) Stone Basket
Ergonomically Designed Kidney Stone Retrieval Basket CHANDLER, Ariz., Dec. 4, 2018 -- (Healthcare Sales & Marketing Network) -- MED-Fibers, Inc. announces the distribution of MED-Fibers, Inc. GrabHold™ Stone Basket with its Nitinol and tipless design a... Devices, Urology, Distribution MED-Fibers, GrabHold, Stone Basket, nitinol, ureteroscope (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 4, 2018 Category: Pharmaceuticals Source Type: news